Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a first-in-human, multi-center trial to study the effects of SRP-1005 in adults diagnosed with Huntingtons disease HD. This phase 1 study aims to evaluate the treatments safety and how the body processes SRP-1005, a drug administered by subcutaneous injection. The trial involves participants at specific stages of HD to better understand the impact of this investigational medication. Participants are randomly assigned to one of four groups receiving different doses of SRP-1005 or a placebo. All treatments are given by subcutaneous injection, with the study designed to carefully monitor each dose level. This randomized, double-blind, placebo-controlled trial includes dose escalation to assess safety and the drugs behavior at various concentrations. During the study, participants will undergo regular assessments to monitor adverse events and measure SRP-1005 levels in plasma, urine, and cerebrospinal fluid. The trial includes lumbar punctures and MRI scans as part of safety and feasibility evaluations. The main focus is on tracking any treatment-related side effects through week 24, with additional monitoring of drug concentration up to day 17 and cerebrospinal fluid levels through week 24. Participants are expected to be involved for about six months, including safety follow-up.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and potential to slow disease progression of votoplam in adults with early symptomatic Huntingtons disease. This phase 3 study compares votoplam to a placebo in a double-blind, randomized design sponsored by Novartis Pharmaceuticals. The study focuses on measuring changes in clinical scores that reflect disease status and progression over time. Participants will be randomly assigned in a 32 ratio to receive either votoplam or a placebo orally. The study includes three periods a screening phase lasting up to 42 days to determine eligibility a double-blind treatment phase with a variable duration of up to 36 months, where not all participants will complete the full duration and a safety follow-up period consisting of one visit or phone call approximately 30 days after the end of the study. The treatment period ends when at least 50% of participants reach month 36. During participation, individuals will undergo various assessments including clinical rating scales such as the composite Unified Huntingtons Disease Rating Scale cUHDRS, functional capacity scores, motor scores, cognitive tests, and blood tests to measure mutant huntingtin protein levels and neurofilament light chain. Safety will be monitored throughout for adverse events. The study aims to gather detailed information on both the effects and safety of votoplam over the treatment period and shortly after treatment ends.
Actively Recruiting
Healthy Volunteer
Researchers are conducting Enroll-HD, a large, ongoing observational study that combines and expands previous Huntingtons disease HD registries across multiple continents, including Europe, North America, Australasia, and Latin America. This study collects longitudinal clinical data and biological samples from individuals with manifest HD, those carrying or at risk of carrying the HD gene mutation, and control participants without the mutation. The goal is to build a rich database to support research into disease progression, prognosis, and developing clinical trial endpoints. Participants include those with diagnosed HD, pre-manifest carriers, relatives with unknown or negative genotype status, family controls, and community controls. The study involves annual assessments with no planned end date, allowing for long-term data collection. Researchers collect demographic, clinical, family history, genetic, and blood sample information systematically from over 150 sites worldwide. During the study, participants undergo motor, functional, behavioral, and cognitive assessments using standardized tools such as the Unified Huntingtons Disease Rating Scale and Problem Behaviors Assessment-Short. Data are updated at each visit, including clinical signs and genotyping results. The study database is periodically made available to researchers globally, and participants may contribute for many years, helping to advance understanding and support future interventional studies in HD.